CD163 and cancer: The ectopic expression of CD163 on cancer cells due to cell fusion has been experimentally validated [119], has been reported in several cancer types [115,120,121] and seems like a common and valid mechanism that needs to be considered in the design of anti-cancer immunotherapeutic approaches.